Development Research Program

项目摘要 DRP的目标是支持创新和科学上有价值的研究项目，可以翻译 影响乳腺癌诊断和管理的临床重要应用，以减少 负担和死亡率。DRP将：1）鼓励和征求创新的转化实验室， 人口和临床研究建议; 2）鼓励和支持跨学科合作，在翻译 乳腺癌研究; 3）产生新的假设，可以在更大规模的研究项目中进行测试。 这一支持将扩大SPORE的研究组合。发展研究计划将提供 一年50，000美元的直接费用（25，000美元来自SPORE基金，25，000美元来自马约诊所癌症中心）， 六个项目。此外，DRP将为5个项目中的每个项目提供额外的25，000美元直接费用/年。 年来支持一个由一个代表性不足的种族和族裔群体的调查员领导的项目。这将 与来自马约诊所癌症中心或我们的合作机构的额外25 K相匹配， 明尼苏达大学共济会癌症中心和埃默里癌症中心。在所有情况下， 预计第二年的支助将取决于是否取得足够的进展。已经建立了一个程序， 包括呼吁申请和利用内部科学顾问的专业知识进行正式的同行评审 和其他有经验的研究人员。选择供资项目的标准是基于 科学价值，原创性，申请人的资格和翻译潜力。预计支持 发展研究项目的成果将产生数据，这些数据将作为进一步研究的基础。 SPORE赞助的项目或通过同行评审的外部赠款支持提供的支持。三个主要指标 DRP的生产力是DRP项目的进步，以一个完整的项目在SPORE，收购校外 资助和项目获奖者的出版物。共有41名DRP获奖者，其中四个奖项是 于2020年9月1日发布。目前赠款的11个SPORE项目中有6个（2个），以前的赠款（2个）， 和更新（两个）有一个共同领导人谁是DRP获奖者。36名残疾人士退休计划得奖者（九月一日前， 2020年）已获得17个R 01，9个基金会赠款，3个科门赠款，一个明尼苏达州赠款，一个 R21，一个美国癌症研究协会赠款，一个美国癌症协会赠款，一个鹰的 赠款，一个再生医学明尼苏达州赠款，和三个乳房孢子职业增强奖，在 除了五名获奖者谁已提前到共同领导的一个完整的项目在乳房孢子。这些 36位获奖者在同行评审期刊上发表了115篇与DRP项目相关的手稿。的DRP 已经非常成功地确定了调查人员的干部，扩大和丰富了科学的， 这是一个完整的项目组合，并提供了一个机制，以发展共同领导人在整个项目。

PROJECT SUMMARY The goal of the DRP is to support innovative and scientifically meritorious research projects that can be translated into clinically important applications impacting diagnosis and management of breast cancer to decrease the burden and mortality from this disease. The DRP will: 1) encourage and solicit innovative translational laboratory, population, and clinical study proposals; 2) encourage and support interdisciplinary collaboration in translational research in breast cancer; and 3) generate new hypotheses that can be tested in larger-scale research projects. This support will expand the research portfolio of the SPORE. The Developmental Research Program will provide $50,000 direct costs for one year ($25,000 from SPORE funds and $25,000 from Mayo Clinic Cancer Center) to each of six projects. Additionally, the DRP will provide an additional $25,000 direct costs/year for each of the 5 years to support one project led by an investigator from an underrepresented racial and ethnic group. This will be matched with an additional 25K from the Mayo Clinic Cancer Center or our collaborating institutions, University of Minnesota Masonic Cancer Center and Emory Cancer Center. In all cases, there will be the expectation of a second year of support contingent on sufficient progress. A process has been established involving a call for applications and a formal peer review utilizing the expertise of the Internal Scientific Advisory Committee and other experienced investigators. Criteria for selection of projects for funding are based upon scientific merit, originality, qualifications of the applicant, and translational potential. It is expected that support of developmental research projects will result in generation of data that will serve as the basis for additional SPORE-sponsored projects or support through peer-reviewed external grant support. The three main metrics for productivity of the DRP are advancement of DRP projects to a full Project in the SPORE, acquisition of extramural funding, and publications by the project awardees. There have been 41 DRP awardees with four awards being made on September 1, 2020. Six of the eleven SPORE projects in the current grant (two), previous grant (two), and renewal (two) have a Co-Leader who was a DRP awardee. The 36 DRP awardees (before September 1, 2020) have obtained 17 R01s, nine Foundation grants, three Komen grants, one State of Minnesota grant, one R21, one American Association for Cancer Research grant, one American Cancer Society grant, one Eagle’s grant, one Regenerative Medicine Minnesota grant, and three Breast SPORE Career Enhancement Awards, in addition to the five awardees who have advanced to Co-Leadership of a full project in the Breast SPORE. These 36 awardees have published 115 manuscripts related to their DRP projects in peer-reviewed journals. The DRP has been highly successful in identifying cadre of investigators that has expanded and enriched the scientific portfolio of the SPORE and provided a mechanism for development of Co-Leaders in full Projects.